Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo Sees Regulatory Setting For Opana ER As "A Moving Target"

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO says company in discussions about "complete response" letter with FDA and will "work through" FDA's safety-first focus.

You may also be interested in...



Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH

Additional research into abuse-deterrent and non-addictive drug formulations is expected as part of the Obama Administration’s prescription drug abuse plan, some of which already is under way.

Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance

FDA’s response to new data on Remoxy could serve as a model for how the agency expects to deal with the abuse-deterrent formulations it is encouraging for oxycodone and other opioids.

Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH

Additional research into abuse-deterrent and non-addictive drug formulations is expected as part of the Obama Administration’s prescription drug abuse plan, some of which already is under way.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel